迷幻洋菇市場規模、佔有率和成長分析（按蘑菇類型、產品形式、應用、分銷管道和地區分類）：產業預測（2026-2033 年）

2024 年全球迷幻洋菇市場價值 12.8 億美元，預計到 2025 年將成長至 13.8 億美元，到 2033 年將成長至 25 億美元，在預測期（2026-2033 年）內複合年成長率為 7.7%。

全球迷幻洋菇市場涵蓋了含裸蓋菇素真菌（尤其是裸蓋菇屬真菌）的種植、分銷和治療用途，這些真菌在精神健康治療方面的潛力已得到認可。人們對有效治療憂鬱症和創傷後壓力症候群（PTSD）的需求日益成長，而傳統藥物往往無法充分解決這些問題，這推動了該市場的重要性。雖然該領域曾經主要處於地下狀態，但近期的臨床試驗使相關研究合法化，吸引了投資者的興趣，並促成了受監管供應鏈的出現。裸蓋菇素在多個地區的非刑事化和接受度不斷提高，擴大了患者群體，吸引了資金，並促使企業從非法生產轉向合法生產。此外，人工智慧驅動的分析正在改變產品開發，透過改進種植技術、提高監管合規效率和支援個人化治療，加速創新並最佳化市場成長潛力。

全球迷幻洋菇市場的成長要素

隨著臨床研究的不斷積累，裸蓋菇素化合物在治療憂鬱症、焦慮症和物質使用障礙等精神健康問題方面的潛力日益受到關注。這些迅速傳播的科學證據正在增強醫療專業人員、投資者和患者的信心。隨著這些療法的有效性得到更廣泛的認可，與製藥公司的合作也變得越來越普遍，吸引了投資，並為標準化配方的開發鋪平了道路。對合法來源的蘑菇產品日益成長的需求迫使生產商加強其生產和分銷能力，從而推動了市場成長。此外，這種更廣泛的接受度也促進了這些創新療法融入常規醫療實踐，例如促進臨床試驗受試者的招募，並促使保險公司考慮將其納入承保範圍。

全球迷幻洋菇市場的限制因素

由於各國和地區監管環境分散且不一致，全球迷幻洋菇市場面臨嚴峻挑戰。這種監管差異為試圖跨境營運的公司帶來了不確定性，因為某些地區可能實施嚴格的禁令，而另一些地區則允許有限的醫療用途。這種監管不一致使策略規劃複雜化，增加了合規成本，並最終阻礙了長期基礎建設投資。此外，潛在合作夥伴可能不願建立國際夥伴關係，經銷商也難以滿足各種不同的授權要求。因此，公司往往將業務限制在法律穩定的地區，從而阻礙了整體市場成長，限制了消費者的認知和接受度，並最終抑制了需求。

全球迷幻洋菇市場趨勢

全球迷幻洋菇市場正呈現出將基於裸蓋菇素的療法融入主流醫療保健的顯著趨勢。在強力的臨床證據和日益成長的患者需求的推動下，醫療服務提供者正積極將這些療法納入心理健康診療方案。這項轉變促進了製藥公司、生物技術創新者和醫院網路之間的合作，從而建立了標準化的劑量方案和培訓項目，並推動了保險報銷機制的完善。隨著社會接受度的提高，保險公司也開始考慮將迷幻蘑菇療法納入健保範圍，迷幻藥理學也擴大被納入醫學教育。這正在改善各個區域市場獲取和永續性蘑菇衍生療法的途徑。

目錄

介紹

• 分析目的
• 市場定義和範圍

分析方法

• 分析過程
• 二級資料和一級資料的方法
• 估算市場規模的方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態與展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特五力分析及其影響

關鍵市場觀察

• 主要成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 市場魅力指數（2025）
• PESTLE分析
• 監理情勢

全球迷幻洋菇市場規模：依蘑菇類型分類

• 南方裸蓋菇（Psilocybe Cubensis）
• 裸蓋菇（Psilocybe semilanceata）
• 其他種類的裸蓋菇
• 鵝膏屬
• 其他

全球迷幻洋菇市場規模：依產品類型分類

• 新鮮的
• 乾貨
• 提煉
• 膠囊
• 食用產品
• 其他

全球迷幻洋菇市場規模：按應用領域分類

• 治療研究
• 心理健康研究
• 僅供娛樂
• 其他

全球迷幻洋菇市場規模：依分銷管道分類

• 專賣店
• 線上管道
• 其他

全球迷幻洋菇市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭格局

• 前五大公司對比
• 主要公司的市場定位（2025 年）
• 主要公司採取的策略
• 近期市場趨勢
• 主要公司市佔率（2025 年）
• 主要公司簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 2023-2025年營收年比比較

主要公司簡介

• COMPASS Pathways plc
• Cybin Inc.
• MindMed Inc.
• Atai Life Sciences NV
• GH Research PLC
• Beckley Psytech Limited
• Usona Institute
• MAPS Public Benefit Corporation
• Filament Health Corp.
• Small Pharma Ltd.
• Red Light Holland Corp.
• Silo Wellness, Inc.
• Seelos Therapeutics, Inc.
• Psilera Inc.
• Delix Therapeutics, Inc.
• Psylo Therapeutics
• Enveric Biosciences, Inc.
• MagicMed Industries Inc.
• Bright Minds Biosciences Inc.
• Optimi Health Corp.

結論與建議

Global Psychedelic Mushroom Market size was valued at USD 1.28 Billion in 2024 and is poised to grow from USD 1.38 Billion in 2025 to USD 2.5 Billion by 2033, growing at a CAGR of 7.7% during the forecast period (2026-2033).

The global psychedelic mushroom market encompasses the cultivation, distribution, and therapeutic use of psilocybin-containing fungi, particularly Psilocybe species, recognized for their potential in mental health treatments. The growing demand for effective therapies for depression and PTSD, where traditional pharmaceuticals often fall short, fuels market relevance. Once dominated by underground activities, recent clinical trials have legitimized research, drawing investor interest and leading to the emergence of regulated supply chains. Decriminalization and rising acceptance of psilocybin in multiple regions expand the patient base and attract funding, transitioning companies from illicit to certified production. Furthermore, AI-driven analytics are transforming product development, enhancing cultivation techniques, streamlining regulatory compliance, and supporting personalized therapies, thus accelerating innovation and optimizing market growth potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Psychedelic Mushroom market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Psychedelic Mushroom Market Segments Analysis

Global psychedelic mushroom market is segmented by mushroom type, product form, application, distribution channel and region. Based on mushroom type, the market is segmented into Psilocybe Cubensis, Psilocybe Semilanceata, Other Psilocybe Species, Amanita Species and Others. Based on product form, the market is segmented into Fresh, Dried, Extracts, Capsules, Edibles and Others. Based on application, the market is segmented into Therapeutic Research, Mental Health Research, Recreational Use and Others. Based on distribution channel, the market is segmented into Specialty Stores, Online Channels and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Psychedelic Mushroom Market

The growing body of clinical research is highlighting the therapeutic potential of psilocybin-based compounds in addressing mental health issues such as depression, anxiety, and substance use disorders. This burgeoning scientific validation fosters increased confidence among healthcare professionals, investors, and patients alike. As these treatments gain recognition for their benefits, partnerships with pharmaceutical companies are becoming more prevalent, subsequently attracting financial investments and paving the way for the creation of standardized formulations. The rising demand for legally sourced mushroom products is driving manufacturers to enhance their production and distribution capabilities, thereby fueling market growth. Additionally, this acceptance aids in the recruitment for clinical trials and encourages insurance providers to explore coverage options, promoting the integration of these innovative therapies into conventional healthcare practices.

Restraints in the Global Psychedelic Mushroom Market

The global psychedelic mushroom market faces considerable challenges due to the inconsistent and fragmented landscape of national and regional regulations. This divergence creates uncertainty for businesses attempting to operate across borders, as some areas impose stringent prohibitions while others permit restricted medical applications. Such regulatory discrepancies complicate strategic planning and inflate compliance costs, ultimately dissuading investment in long-term infrastructural development. Additionally, potential collaborators may be reluctant to pursue international partnerships, and distributors encounter difficulties in meeting diverse licensing requirements. As a result, companies often confine their operations to legally stable regions, hindering the overall growth of the market and limiting consumer awareness and acceptance, which in turn restricts demand.

Market Trends of the Global Psychedelic Mushroom Market

The global psychedelic mushroom market is witnessing a notable trend towards the integration of psilocybin-based therapies into mainstream healthcare. Driven by compelling clinical evidence and increasing patient demand, healthcare providers are actively incorporating these treatments into their mental health protocols. This transformation spurs collaborations among pharmaceutical companies, biotechnology innovators, and hospital networks to establish standardized dosing regimens and training programs, as well as developing reimbursement frameworks. With growing societal acceptance, insurance providers are beginning to explore coverage options, while medical education increasingly includes psychedelic pharmacology, enhancing the accessibility and sustainability of mushroom-derived therapeutics across various regional markets.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Psychedelic Mushroom Market Size by Mushroom Type & CAGR (2026-2033)

• Market Overview
• Psilocybe Cubensis
• Psilocybe Semilanceata
• Other Psilocybe Species
• Amanita Species
• Others

Global Psychedelic Mushroom Market Size by Product Form & CAGR (2026-2033)

• Market Overview
• Fresh
• Dried
• Extracts
• Capsules
• Edibles
• Others

Global Psychedelic Mushroom Market Size by Application & CAGR (2026-2033)

• Market Overview
• Therapeutic Research
• Mental Health Research
• Recreational Use
• Others

Global Psychedelic Mushroom Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Specialty Stores
• Online Channels
• Others

Global Psychedelic Mushroom Market Size & CAGR (2026-2033)

• North America (Mushroom Type, Product Form, Application, Distribution Channel)
  • US
  • Canada
• Europe (Mushroom Type, Product Form, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Mushroom Type, Product Form, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Mushroom Type, Product Form, Application, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Mushroom Type, Product Form, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• COMPASS Pathways plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cybin Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MindMed Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Atai Life Sciences N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GH Research PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckley Psytech Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Usona Institute
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MAPS Public Benefit Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Filament Health Corp.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Small Pharma Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Red Light Holland Corp.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Silo Wellness, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seelos Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Psilera Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Delix Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Psylo Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Enveric Biosciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MagicMed Industries Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bright Minds Biosciences Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Optimi Health Corp.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations